Independent Commissioning Agent (Owner’s Advocate) Services for U.S. Army Medical Research Institute of Infectious Diseases

Was der Auftraggeber sucht

THIS IS A REQUEST FOR INFORMATION (RFI)/SOURCES SOUGHT (SS) NOTIFICATION INCLUDING INDUSTRY FEEDBACK 1. Title: Independent Commissioning Agent (Owner’s Advocate) Services for U.S. Army Medical Research Institute of Infectious Diseases 2. Contracting Office: Defense Health Agency Contracting Activity (DHACA), R&D Contracting Division 1 - Branch 4 3. Location: Fort Detrick, Frederick, MD 4. Summary: This RFI/SS is issued solely for information and planning purposes and shall not be construed as a solicitation, restrict the Government as to the ultimate acquisition approach, or serve as an obligation on the part of the USAMRDC. In accordance with FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are advised that the United States Government will not pay for any information or administrative costs incurred in response to this RFI. All costs associated with responding to this RFI/SS will be solely at the interested responder’s expense. Not responding to this RFI/SS does not preclude participation in any future Request for Proposal, if any is issued. No evaluation letters and/or results will be issued to Responders responding to this RFI/SS. The information resulting from this RFI/SS will determine interest and capabilities available in the marketplace; and will assist in developing acquisition strategy. 5. Background: The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), located at Fort Detrick, Maryland, is the premier lead medical research laboratory for the U.S. Department of War's biological defense research program. Since 1969, USAMRIID has provided leading edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute is the only laboratory in the Department of Defense equipped to safely study highly hazardous pathogens requiring maximum containment at Biosafety Level 4. USAMRIID has executed its mission from Building 1425. While historically significant, the legacy facility has surpassed its design lifespan. To sustain the DoD's biosafety integrity and research posture, the Department authorized the design and construction of a state-of-the-art replacement facility: Building 8100. Groundbreaking for the replacement complex took place in August 2009. In 2013, during the final construction execution and fit-out phases, Building 8100 experienced a fire that damaged critical mechanical, electrical, and plumbing infrastructure, Building Automation System controls, and associated laboratory boundary zones. Recovering from this event and achieving facility handover has become an acute operational hardship for the biodefense mission, delaying the transfer of ongoing medical research from the aging legacy facility. Note: Primary physical repair, mechanical completion, and prime construction execution are administered by the U.S. Army Corps of Engineers (USACE). The Contractor shall not draft new architectural designs, stamp or seal engineering drawings, or execute physical facility redesigns. 6. Scope: The Government requires an independent, third-party technical Commissioning Agent (Owner's Advocate) to bridge the technical divide between USACE/prime construction execution and the stringent operational, biosafety, and regulatory compliance requirements of the end-user (USAMRDC Headquarters and USAMRIID). The Commissioning Agent will independently evaluate, witness, and verify critical facility systems and controls, and systematically advise the Government on executing a staggered/phased transition to achieve functional occupancy, biosafety accreditation, and facility registration. How to Respond: Please submit a Capability Statement that describes relevant experience, expertise, and capabilities based upon the size and scope of this requirement as outlined in the draft Statement of Objectives (SOO). Capability statements will be reviewed/evaluated for (1) Relevant experience…

Sprache dieser Bekanntmachung: English. Titel und Beschreibung erscheinen genau so, wie der Auftraggeber sie veröffentlicht hat.

How this compares

• Bidders were given 31 days from publication to the deadline; the median for open tenders in Vereinigte Staaten is 22 days.

More open tenders from this buyer